Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RB 90740

Known as: RB-90740, RB90740 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1996
1996
RB90740 is the lead compound in a series of fused pyrazine mono-N-oxide bioreductive drugs. Theses agents have potential… Expand
Is this relevant?
1996
1996
Pulse radiolysis was used to generate radicals from one electron reduction of 1,2,4-benzotriazine-1,4-dioxides (derivatives of… Expand
Is this relevant?
1996
1996
Potential oncogenicity must be a factor of concern in the design and development of novel bioreductive drugs. In the present… Expand
Is this relevant?
1995
1995
RB 90740 is the lead compound in a series of aromatic mono-N-oxide bioreductive drugs. The compound shows considerably greater… Expand
Is this relevant?
1994
1994
PURPOSE To compare the effect on the RIF-1 murine sarcoma of nine bioreductive agents from five different classes when used in… Expand
Is this relevant?
1994
1994
PURPOSE To study the reduction of RB90740 (1), a fused pyrazine mono-N-oxide that has an oxic:hypoxic cytotoxicity ratio of > 10… Expand
Is this relevant?
Review
1994
Review
1994
A series of imidazo [1,2-a] quinoxaline mono-N-oxides and their aza- analogues have been synthesized together with analogues… Expand
Is this relevant?